Medical

Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler outside of the US, and QVA149 is marketed as Ultibro Breezhaler outside of the US. According to the data presented … [Read more...] about Positive results from Phase 3 trials of NVA237 and QVA149

Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015. According to Sunovion, the studies show that Brovana produces clinically significant improvement in health status compared to placebo, that only about half of COPD patients in hospital get long acting … [Read more...] about Sunovion announces results of Brovana studies

Boehringer Ingelheim Pharmaceuticals has presented new data analyses from two Phase 3 studies of its tiotropium/olodaterol Respimat SMI for the treatment of COPD at ATS 2015. The two efficacy and safety studies (NCT01431274 and NCT01431287), compared a fixed dose tiotropium/olodaterol combination delivered by the Respimat inhaler to each of the individual components … [Read more...] about Boehringer Ingelheim presents new data analysis from tiotropium/olodaterol Respimat studies

In a note accompanying a set of articles on the impact of the FDA's ban on the use of CFC propellants in metered dose inhalers and the transition to HFA inhalers, published online on May 11, 2015, the editors of JAMA Internal Medicine suggest that while any potential ecological benefits of the ban remain unclear, the benefits to the pharmaceutical industry are … [Read more...] about JAMA Internal Medicine articles on the impact of the CFC to HFA transition criticize FDA and pharmaceutical companies

Adamis Pharmaceuticals has announced that a clinical study comparing its APC-2000 albuterol MDI with GSK's Ventolin Evohaler MDI met its primary endpoint, showing equivalence in change from baseline of FEV1 for both doses tested (100 and 200 mcg). The company said that the study, which involved 124 patients with mild to moderate asthma, took place "outside of the … [Read more...] about Positive results for Adamis Pharmaceutical’s generic albuterol MDI

Verona Pharma has announced what it calls "encouraging interim results" from a Phase 1/2 study of a new formulation of its RPL554 PDE3/4 inhibitor for the treatment of COPD exacerbations. The company had announced the initiation of the 120-subject study of the nebulized formulation in January 2015 and now says that the trial is ahead of schedule. According to … [Read more...] about Verona says interim results from Phase 1/2 study of RPL554 look promising

A public/private partnership in Louisville, Kentucky called AIR Louisville will distribute 2,000 Propeller Health inhaler sensors to asthma patients across the city as part of a 2-year data collection program, according to Propeller. The FDA approved an updated version of the asthma tracking system, which includes sensors that snap onto standard MDIs, in April 2014. … [Read more...] about Louiville, KY launches citywide inhaler sensor distribution program

AstraZeneca has announced that data from two Phase 3 studies of its PT003 glycopyrronium/formoterol MDI for the treatment of COPD showed statistically significant improvements in lung function for patients using PT003 compared to each of its components and to placebo. In 2013, Pearl Therapeutics announced the initiation of the Phase 3 program less than a month before … [Read more...] about Positive Phase 3 results for PT003 glycopyrronium/formoterol MDI